银杏内酯注射液治疗缺血性脑卒中恢复期的临床观察

发布时间：2018-07-15 19:24

【摘要】：目的：观察银杏内酯注射液治疗缺血性脑卒中恢复期的临床疗效及安全性。方法：将符合诊断标准的56例缺血性脑卒中恢复期患者，采用随机法分为银杏内酯注射液治疗组25例和银杏达莫注射液对照组31例。因病例脱落，最后完成临床研究观察的患者共54例，分别为治疗组24例、对照组30例。治疗组采用银杏内酯注射液50mg+0.9%氯化钠250ml静脉滴注，每天1次，1个疗程为2周。对照组采用银杏达莫注射液20ml+0.9%氯化钠250ml静脉滴注，每天1次，1个疗程为2周。观察患者神经功能缺损程度、日常生活活动能力、临床综合疗效、血液学指标及用药不良反应方面的变化。结果：（1）神经功能缺损评分：银杏内酯注射液治疗组治疗前后评分分别为3.1±2.953、2.5±2.782，治疗后较治疗前有改善（P0.05)。（2）日常生活活动能力评分：银杏内酯注射液治疗组治疗前后评分分别为1.8±1.203、1.3±0.963治疗后较治疗前有改善(P0.05)。（3）临床综合疗效：银杏内酯注射液治疗组有1例基本痊愈，4例显著进步，2例进步，17例无效，总有效率29.0％；银杏达莫注射液对照组有3例基本痊愈，5例显著进步，2例进步，20例无效，总有效率34.0％，两组治疗均有效，两组治疗有效率有统计学差异(P0.05)，，对照组临床综合疗效改善优于治疗组。（4）安全性评估：银杏内酯注射液治疗组有2例出现不良反应，生命体征、血常规、尿常规、心肌酶、凝血功能、心电图、大便常规+OB等指标进行治疗前后对比，P0.05，无统计学差异。TBIL治疗前后比较分别为3.4±5.670、11.2±3.733, P0.05，有统计学差异，BUN治疗前后比较分别为5.3±1.512、4.6±1.257，P0.05，有统计学差异，说明该药能改善肝肾功能。ALT、AST、GGT、ALP、Cr、尿酸等指标两组治疗前后对比，P0.05，无统计学差异。结论：银杏内酯注射液治疗恢复期缺血性脑卒中是有效的，能促进神经功能缺损恢复，提高日常生活活动能力，同时能改善肝肾功能，安全性有待扩大样本量进一步验证。
[Abstract]:Objective: to observe the clinical efficacy and safety of ginkgolide injection in the convalescence of ischemic stroke. Methods: 56 patients with ischemic stroke in convalescence were randomly divided into Ginkgolide injection group (n = 25) and Ginkgo biloba injection control group (n = 31). A total of 54 patients, 24 in the treatment group and 30 in the control group, completed the clinical observation because of the abscission of the cases. Ginkgolide injection 50mg 0.9% sodium chloride 250ml was injected intravenously once a day for 2 weeks in the treatment group. The control group was treated with 20ml 0.9% sodium chloride 250ml once a day for 2 weeks. The degree of neurological deficit, activity of daily living, clinical efficacy, hematologic indexes and adverse drug reactions were observed. Results: (1) neurological deficit score: the scores of Ginkgolide injection group before and after treatment were 3.1 卤2.953 卤2.782, which were improved after treatment (P0.05). (2): Ginkgolide injection treatment group before and after treatment The scores were 1.8 卤1.203 卤0.963 after treatment (P0.05). (3). In Ginkgolide injection group, 1 case was basically cured and 2 cases improved significantly. 17 cases were ineffective. The total effective rate was 29.0. In the Ginkgo biloba injection group, 3 cases were basically cured, 5 cases were significantly improved, 20 cases were ineffective, and the total effective rate was 34.0.The treatment was effective in both groups. There was significant difference in the effective rate between the two groups (P0.05). The improvement of comprehensive clinical efficacy in the control group was better than that in the treatment group. (4) Safety evaluation: there were 2 cases of adverse reactions, vital signs, blood routine, urine routine, myocardial enzymes in the treatment group with ginkgolide injection. Coagulation function, electrocardiogram (ECG) and routine stool OB were compared before and after treatment (P 0.05). There was no statistical difference. TBIL was 3.4 卤5.670,11.2 卤3.733 before and after treatment, P 0.05.The difference before and after treatment was 5.3 卤1.512 卤4.6 卤1.257P0.05, respectively. The results showed that the drug could improve the liver and kidney function. The liver and kidney function of the two groups were improved. There was no statistical difference between the two groups before and after treatment. Conclusion: ginkgolide injection is effective in the treatment of ischemic stroke in convalescent stage. It can promote the recovery of neurological function, improve the ability of daily life, and improve the function of liver and kidney. The safety of Ginkgolide injection needs to be further verified.
【学位授予单位】：遵义医学院
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R743.3

【参考文献】